veliflapon

Action and Spectrum

Actions and Spectrum: 

veliflapon is a selective inhibitor of 5-lipoxygenase activating protein (FLAP). Its action primarily involves modulating the synthesis of leukotrienes, specifically leukotriene B4 (LTB4) and leukotriene C4 (LTC4). The spectrum of veliflapon’s action is primarily related to its potential therapeutic applications in inflammatory conditions, particularly those associated with leukotrienes.

Leukotrienes are potent inflammatory mediators involved in various diseases, together with asthma, chronic obstructive pulmonary disease, and other inflammatory conditions. By inhibiting FLAP, veliflapon reduces the production of leukotrienes and may help modulate the inflammatory response associated with these conditions. 

Drug Interaction

Adverse Reaction

N/A 

Black Box Warning

Black Box Warning: 

None 

Contraindication / Caution

Contraindication/Caution: 

Contraindication 

None 

Caution 

• Adverse Reactions: Like any medication, veliflapon may be associated with potential adverse reactions or side effects. You must be aware of the possible risks and discuss them with your healthcare provider. 
• Drug Interactions: veliflapon may interact with other medications, including prescription drugs, over-the-counter (OTC) drugs, and herbal supplements. To avoid potential drug interactions, it is crucial to inform your healthcare provider about all the drugs you are taking. 
• Allergic Reactions: Individuals with known hypersensitivity or allergy to veliflapon or its components should avoid its use. If you experience signs of an allergic reaction, such as rash, itching, swelling, or difficulty breathing, seek immediate medical attention. 
• Pregnancy and Breastfeeding: The safety of veliflapon during pregnancy and breastfeeding has not been established. If you are pregnant, planning to become pregnant, or breastfeeding, discussing the potential risks and benefits of using veliflapon with your healthcare provider is essential. 
• Liver Function: veliflapon may have an impact on liver function. Individuals with pre-existing liver disease or impairment may require close monitoring while taking veliflapon. 
• Kidney Function: veliflapon’s effect on kidney function has not been extensively studied. If you have kidney disease or impaired renal function, discussing potential risks and appropriate monitoring with your healthcare provider is important. 
• Pre-existing Medical Conditions: Inform your healthcare provider about any pre-existing medical conditions you have, such as cardiovascular disease, respiratory disorders, or any other relevant conditions. These factors may influence the decision to prescribe veliflapon or require close monitoring during treatment. 

Pregnancy / Lactation

Pregnancy consideration:  

US FDA pregnancy category: Not assigned. 

Lactation:   

Excreted into human milk: Not known. 

Pregnancy category: 

• Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester. 
• Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. 
• Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    
• Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    
• Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    
• Category N: There is no data available for the drug under this category 

Pharmacology

Pharmacology: 

veliflapon is a compound that acts as a FLAP (5-lipoxygenase activating protein) inhibitor. FLAP inhibitors, including veliflapon, are being studied for their potential in treating inflammatory diseases. The compound is DG-031/BAYX1005 and has reached phase III clinical trials for treating myocardial infarction and heart attacks. 

FLAP inhibitors, such as veliflapon, target the 5-lipoxygenase (5-LO) enzyme responsible for generating cysteinyl-leukotrienes (cys-LTs) and leukotriene B4 (LTB4). By inhibiting FLAP, veliflapon reduces the synthesis of leukotrienes B4 and C4. Leukotrienes are inflammatory mediators involved in asthma and other inflammatory conditions. 

Pharmacodynamics: 

Mechanism of action: veliflapon is a 5-lipoxygenase activating protein (FLAP) inhibitor. It selectively inhibits FLAP, which activates the 5-lipoxygenase (5-LO) enzyme involved in synthesizing leukotrienes. 

Leukotrienes are inflammatory mediators involved in asthma and other inflammatory conditions. By inhibiting FLAP, veliflapon reduces the production of leukotrienes, specifically leukotriene B4 (LTB4) and leukotriene C4 (LTC4). This inhibition of leukotriene synthesis helps to modulate the inflammatory response associated with these conditions. 

The exact mechanism of action of veliflapon involves binding to FLAP and interfering with its activation process, thereby reducing the availability of 5-LO and subsequently inhibiting the production of leukotrienes. By targeting this critical step in leukotriene biosynthesis, veliflapon aims to alleviate the inflammatory processes that contribute to diseases such as asthma and potentially other inflammatory conditions. 

Pharmacokinetics: 

N/A 

Adminstartion

Administration: 

In general, veliflapon is available in oral form. Oral medications are typically taken by mouth with water or as directed by healthcare professionals. The dosing schedule and duration of treatment will be determined based on the specific condition and individual patient factors. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: veliflapon 

Why do we use veliflapon? 

veliflapon is being investigated for several potential uses. 

• Myocardial Infarction and Heart Attacks: veliflapon has reached phase III clinical trials to treat myocardial infarction (heart attack). It is being studied for its potential to reduce the impact and improve outcomes in these conditions.